Lee Ainslie Exelixis, Inc. Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $686,774 - $948,651	-43,357 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $238,648 - $309,510	-14,641 Reduced 25.24%	43,357 $917,000
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $704,609 - $1 Million	39,254 Added 209.42%	57,998 $1.06 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $384,814 - $472,723	18,744 New	18,744 $423,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $1.33 Million - $2 Million	-91,759 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $582,684 - $726,528	38,461 Added 72.16%	91,759 $1.62 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $942,308 - $1.21 Million	53,298 New	53,298 $943,000

500

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.